@article {606029,
	title = {Improved adherence adjustment in the Coronary Drug Project},
	journal = {Trials},
	volume = {19},
	year = {2018},
	pages = {158},
	abstract = {BackgroundThe survival difference between adherers and non-adherers to placebo in the Coronary Drug Project has been used to support the thesis that adherence adjustment in randomized trials is not generally possible and, therefore, that only intention-to-treat analyses should be trusted. We previously demonstrated that adherence adjustment can be validly conducted in the Coronary Drug Project using a simplistic approach. Here, we re-analyze the data using an approach that takes full advantage of recent methodological developments.MethodsWe used inverse-probability weighted hazards models to estimate the 5-year survival and mortality risk when individuals in the placebo arm of the Coronary Drug Project adhere to at least 80\% of the drug continuously or never during the 5-year follow-up period.ResultsAdjustment for post-randomization covariates resulted in 5-year mortality risk difference estimates ranging from - 0.7 (95\% confidence intervals (CI), - 12.2, 10.7) to 4.5 (95\% CI, - 6.3, 15.3) percentage points.ConclusionsOur analysis confirms that appropriate adjustment for post-randomization predictors of adherence largely removes the association between adherence to placebo and mortality originally described in this trial.},
	url = {https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2519-5},
	author = {Murray, Eleanor J and Hernan, Miguel A}
}
